PANITUMUMAB

Search structure
Trade Names:
Synonyms:
Status: Approved (2006)
Entry Type: Antibody
Molecule Category: UNKNOWN
ATC: L01XC08
UNII: 6A901E312A

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Epidermal growth factor receptor erbB1 inhibitor DailyMed
Primary Target
epidermal growth factor receptor

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Colorectal Neoplasms 4 D015179 ClinicalTrials
Colorectal Neoplasms 4 D015179 ClinicalTrials
Colorectal Neoplasms 4 D015179 ClinicalTrials
Neoplasms 4 D009369 ClinicalTrials
Colonic Neoplasms 3 D003110 ClinicalTrials
Carcinoma, Squamous Cell 3 D002294 ClinicalTrials
Carcinoma, Squamous Cell 3 D002294 ClinicalTrials
Head and Neck Neoplasms 3 D006258 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Stomach Neoplasms 2 D013274 ClinicalTrials
Carcinoma, Renal Cell 2 D002292 ClinicalTrials
Esophageal Neoplasms 2 D004938 ClinicalTrials
Rectal Neoplasms 2 D012004 ClinicalTrials
Cholangiocarcinoma 2 D018281 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 2 D002289 ClinicalTrials
Esophageal Neoplasms 2 D004938 ClinicalTrials
Pancreatic Neoplasms 2 D010190 ClinicalTrials
Malignant Carcinoid Syndrome 2 D008303 ClinicalTrials
Urinary Bladder Neoplasms 2 D001749 ClinicalTrials
Fallopian Tube Neoplasms 2 D005185 ClinicalTrials
Carcinoma 2 D002277 ClinicalTrials
Uterine Cervical Neoplasms 2 D002583 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Esophageal Neoplasms 2 D004938 ClinicalTrials
Ovarian Neoplasms 2 D010051 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 2 D064129 ClinicalTrials
Lung Neoplasms 2 D008175 ClinicalTrials
Kidney Neoplasms 1 D007680 ClinicalTrials

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Skin and subcutaneous tissue disorders
17.58
Gastrointestinal disorders
12.95
General disorders and administration site conditions
12.13
Nervous system disorders
6.82
Investigations
6.81
Metabolism and nutrition disorders
6.5
Infections and infestations
5.52
Vascular disorders
3.95
Respiratory, thoracic and mediastinal disorders
3.76
Blood and lymphatic system disorders
3.69
Injury, poisoning and procedural complications
3.58
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
2.7
Immune system disorders
2.44
Cardiac disorders
2.34

Cross References

Resources Reference
CAS NUMBER 339177-26-3
ChEMBL CHEMBL1201827
FDA SRS 6A901E312A
Guide to Pharmacology 6883
CONTENTS